Virological response to different combination regimes of peginterferon α-2b and lamivudine in hepatitis B e antigen positive chronic hepatitis B

Antiviral Therapy

Volumn 12, Issue 5, 2007, Pages 815-823

  Chan, Henry Lik Yuen ^a   Wong, Vincent Wai Sun ^a   Chim, Angel Mei Ling ^a   Choi, Paul Cheung Lung ^a   Chan, Hoi Yun ^a   Hui, Alex Yui ^a   Wong, Grace Lai Hung ^a   Sung, Joseph Jao Yiu ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2B; VIRUS DNA;

ABDOMINAL DISCOMFORT; ADULT; ALLERGIC RASH; ALOPECIA; APPETITE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIZZINESS; DRUG RESPONSE; ERYTHEMA; FEMALE; FEVER; GENOTYPE; HEADACHE; HEPATITIS B; HUMAN; HYPERTHYROIDISM; MALAISE; MALE; MONOTHERAPY; MYALGIA; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SEROCONVERSION; SIDE EFFECT; TREATMENT RESPONSE; WEIGHT REDUCTION;

ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2B; LAMIVUDINE; LIVER; MALE; MIDDLE AGED; PILOT PROJECTS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; VIRUS REPLICATION;

EID: 34547755458     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Chan HLY, Leung NWY, Hui AY, et al. A randomized, controlled trial or combination therapy for chronic hepatitis B: comparing pegylated interferon α-2b and lamivudine with lamivudine alone. Ann Intern Med 2005; 142:240-250.
2. Janssen HLA, van Zonneveld M, Senturk H, et al. Pegylated interferon α-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomized trial. Lancet 2005; 365:123-129.
3. Lau GKK, Piratvisuth T, Luo KX, et al. Peginterferon α-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352:2682-2695.
4. Hui AY, Chan HLY, Cheung A, Cooksley G, Sung JJY. Treatment of chronic hepatitis B virus infection by pegylated interferon: systematic review of 4 randomized studies. Aliment Pharmacol Ther 2005; 22:519-528.
5. Chan HLY, Hui AY, Wong VWS, Chim AML, Wong ML, Sung JJY. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. Hepatology 2005; 41:1357-1364.
6. Lau GKK, Piratvisuth T, Luo KX, et al. Durability of response and occurrence of late response to peginterferon alpna-2a (40KD) [Pegasys] one year post-treatment in patients with HBeAg-positive chronic hepatitis B. 41st Annual Meeting of the European Association for the Study of the Liver. April 26-30, 2006, Vienna, Austria. Abstract 50.
7. Liaw YF, Leung N, Guan R, Lau GKK, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver International 2005; 25:472-489.
8. Perrillo RP, Gish RG, Peters M, et al. Chronic hepatitis B: a critical appraisal of current approaches to therapy. Clin Gastroenterol Hepatol 2006; 4:233-248.
9. Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomized trial. Gut 2000; 46:562-568.
10. Barbaro G, Zechini F, Pellicelli AM, et al. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. J Hepatol 2001; 35:406-411.
11. Schiff ER, Dienstag JL, Karayalcin S, et al. Lamivudine and 24 week lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol 2003; 38:818-826.
12. Serfaty L, Thabut D, Zoulim F, et al. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study. Hepatology 2001; 34:573-577.
13. Boni C, Bertoletti A, Penna A, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998; 102:968-975.
14. Chan HLY, Chui AKK, Lau WY, et al. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation. J Med Virol 2002; 68:182-187.
15. Chan HLY, Tsang SWC, Liew CT, et al. Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection. Am J Gastroenterol 2002; 97:406-412.
16. Lindh M, Andersson AS, Gusdal A. Genotypes, nt 1858 variants, and geographical origin of hepatitis B virus - large-scaled analysis using a new genotyping method. J Infect Dis 1997; 175:1285-1293.
17. Lok AS, Zoulim F, Locarnini S, et al. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol 2002; 40:3729-3734.
18. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126:1750-1758.
19. Sung JJY, Wong ML, Bowden S, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005; 128:1890-1897.
20. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001; 34:785-791.
21. Lai CL, Gane E, Liaw TF, et al. Maximal early HBV suppression is predictive of optimal virological and clinical efficacy in nucleoside-treated hepatitis B patients: scientific observations from a large multinational trial (The GLOBE Study). 56th Annual Meeting of American Association for the Study of Liver Diseases. 11-15 November, 2005, Boston, MA, USA. Abstract 92.
22. Locarnini S, Qi X, Arterburn S, et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB). 40th Annual Meeting of European Association for the Study of the Liver. 13-17 April, 2005, Paris, France. Abstract 36.
23. Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36:687-696.